Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hakim is doing a fine job. Never short-change yourselves and never underestimate the power of compounding.
Cheers!
The problem with flippers is that they do not take advantage of the power of COMPOUNDING GROWTH / COMPOUNDING INTEREST. Flipping each day or frequency only increases the probability or risks of losses.
Cheers!
Lol! Big MAHALOS, brah!
Cheers!
I am whatever is in the best interest for Elite Pharma. Just sharing my thoughts on hypothetical events, which would add value to ELTP and to uplist in the future. Seems investors are not convinced that Elite is the real deal, long-term, value investment. My question is: Will the eventual FDA-approval for ELI-200 be sufficient to get us over the 97-cents hump?
Cheers!
Almost there, boys! A nickel per share is overvalued. Do we see 2-cents per share?
Cheers!
Epic has some valuable assets and manufacturing facilities, I believe.
Cheers!
Having similar DNA sure helps with the argument. Their diversified drug pipeline would continue to bring in more revenues to Elite's coders. Maybe Hakim could broker a merger deal that Epic execs could not refuse.
Cheers!
Speculation aside, an Epic and Elite RM might be lucrative to both parties.
Cheers!
Currently, Elite is "Cheers!"-worthy. We would be even greater with the FDA's approval and see how far we could ride the ELTP train.
Cheers!
Yes, Hakim would make Elite great! It is happening while we speak.
Cheers!
Agreed, if you do not have a long-term investment goals and objectives, then you would not be able some short-term pains along the way. Case in point, those that bought shares and stayed with ELTP in at least March 2011 have 300%-500% gains. A not so bad ROI.
Cheers!
Well, glad to see that your perspective of Elite has changed for the better. By looking at the BIG PICTURE, shareholders should be asking what Elite's drugs could do for society to end the cycle of prescription, pain medication abuse, than to have an attitude of what stock price could do for me.
Cheers!
Should be peanuts for Elite. The Baby Boomer generation are aging and retiring with health-related issues. Sorry, they would demand their pain medication.
Cheers!
Your patience would be rewarded! Elite has been posting record-breaking revenues. Hopefully, this would lead to concessions for a stock buy back to reward loyal longs.
Cheers!
Hey, nice find! An $800 million market should please shareholders and lock the future of Elite. $$$,$$$,$$$$,$$$$
Cheers!
Indeed, Elite has proven time-and-time again that she is the exception and not the BS scam that many have purported to be in penny stocks. Management has been all-business without playing games on its shareholders.
Cheers!
Lol, did you report her to the SEC?
Cheers!
Please read the due diligence estimates.
Cheers!
An FDA-approval for ELI-200 would easily spell a breakout for ELTP to its new 52-week high. Huge upswings are a common occurrence with penny stocks. ELTP is no different.
Cheers!
When Elite has exceeded expectations in terms of revenues/profitability and breakthrough development of the ELI product line, then it would only make sense for the board of directors to reward Hakim on a job well done.
Cheers!
No worries, guys. Ideally, 2-3-cents in Aqua's book is a garage sale. Not bashing the company. The way I see it is if this is a highly risky investment with rewards, then let's level the playing field by buying as low as possible.
Cheers!
Looking to load up when we do. Might as well get in when the stock is undervalued.
Cheers!
I believe the down-price is due to the MMs and professional investors trying to draw in new investors.
Cheers!
Yawn, any new material. The PPS story is getting old. We all know that July would breathe in new life to ELTP. Anyone who would like to position themselves for July breakout should be accumulating within that timeframe.
Cheers!
I have no problem with your assessment. It is indeed conservative to say the least. I will be fully invested in ELTP and would buy shares along the way. Okay, a higher PPS would gravitate towards Elite's financial strength and its ability to develop new drugs/ technology to continue the drive.
Cheers!
March Madness has been good to Elite. Go Hawaii and Cheers!
The 2-cents boogie man is a myth. The due diligence would keep many ELTP investors honest. Saving the best for last.
Cheers!
Some folks never learn when the writing is clearly on the wall. Elite has yet to unlock the beauty of her potential.
Cheers!
Buyouts are a common occurrence in Pharma world. As an investor, I would just focus on our revenues and building the ELI drug pipeline. We know results would come in time. Big MAHALOS for sharing your due diligence, good and bad. The future is set for Elite. The easy part, now, is the green light to buy shares before July. Good luck and Cheers!
That nickel PPS is getting close.
Cheers!
"To be or not to be" best describes an investment in ELTP. After today's PR, I believe Elite is going "to be" an easy $1-$2 PPS company, racking in the revenues to one day uplist to the big boards.
Cheers!
There is always room to learn. $1-$2 PPS is coming sooner than we thought. This time it will stay up through the PPS-Viagra that we call the FDA fast track and FDA-approval of ELI-200. The rest is all gravy.
Cheers!
Someone here called it about an FDA fast track of our ELI-200. When in doubt, always trust your due diligence.
Cheers!
HUGE CHEERS!
Cheers!
Elite will be great 2016!
Cheers!
Pinch my butt, it is Saint Patrick's Day during March Madness. Get ready for a rush for shares. 30-cents is grossly undervalued.
Cheers!
Form 8-K for ELITE PHARMACEUTICALS INC /NV/
17-Mar-2016
Regulation FD Disclosure, Other Events, Financial Statements and E
Item 7.01 Regulation FD Disclosure.
On March 17, 2016, Elite Pharmaceuticals, Inc. ("Elite" or the "Company") issued a press release announcing that its new drug application, or NDA, for SequestOx?, its investigational lead opioid abuse-deterrent drug candidate for the for the management of moderate to severe pain where the use of an opioid analgesic is appropriate, has been accepted and granted priority review by the U.S. Food and Drug Administration, or the FDA. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
Cheers!
Should it not be your right and in your best interest to call investor relations to voice your concerns and opinions. For instance, when the PPS drops, it would be helpful to compile a log to be presented to Dianne. You cannot expect retail investors on this board to have any influence on the PPS.
Cheers!
Yawn, it is obvious that Aqua does not make investment decisions on the PPS alone. It would be reckless to dismiss the potential FDA-approval for ELI-200 and the steady quarterly and annual earnings of at least 30%+. Each investor would need to evaluate Elite from different perspectives to draw accurately which direction the company is going over the long- term.
Cheers!
Sorry, bagholders lives do not matter. Coming from Hawaii, Aqua does not expect the flight duration to Paris, France to be about 2-hours. Patience will get you there.
Cheers!